Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS
Status:
Completed
Trial end date:
1998-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of MSL 109, human monoclonal anti-cytomegalovirus (CMV) antibody, on
time to progression of CMV retinitis. To determine the safety and pharmacokinetic profile of
MS 109. To evaluate the relationship between pharmacokinetic measurements of MSL 109 and
efficacy and virologic markers.
Therapeutic agents currently available for CMV retinitis are limited by their inherent
toxicities and short half-lives which require frequent intravenous dosing. Alternatively, MSL
109 has demonstrated safety and effectiveness in neutralizing CMV isolates at concentrations
easily maintained in AIDS patients.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)